Meek David D. sold $193K of QURE
Meek David D. sold 9,080 shares of uniQure N.V. (QURE) at $21.25 ($0.19M total) on 2026-11-06 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
A director's sale, while small, adds to the flow of insider activity data used by traders.
Market read
The filing provides a fresh, primary‑source data point on insider activity, but its modest size limits trading relevance.
What to watch
The 10b5-1 plan pre‑arranged the sale, reducing the informational content of the transaction.
Background
SEC Form 4 filing discloses insider transactions for public companies.
Ticker impact
Director Meek David D. sold 9,080 shares of uniQure for $192,950 on 2026-11-06.
likely pressure as the market prices in the insider sell
A 10b5-1 planned sale by a director, though modest in size, can be interpreted as a lack of confidence and may prompt short‑term selling.
Market effects
Minimal impact on the gene‑therapy sector; insider sales are routine.
No broader regional effect.
Limited to investors tracking uniQure.
Counterpoint
The sale could be purely liquidity‑driven and not reflect company fundamentals.
Key entities
- companyuniQure N.V.
Gene‑therapy biotech listed on NASDAQ under QURE.
- personMeek David D.
Director of uniQure.



